The trademark application Cerner Enviza was filed by Cerner Innovation, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on October 3, 2021, and it was registered by office on January 10, 2022 without any oppositions.
The application was filed in English (German was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on August 16, 2023.
Goods And Services
The mark was filed in class 9 with Computer software for use in data aggregation, normalization, integration and analysis, data mining and predictive analytics of pharmaceutical, healthcare and life sciences information and Computer software for analyzing data related to patient registries, clinical trials, clinical research and patient management in the pharmaceutical, healthcare and life sciences fields..
The mark was filed in class 42 with following description of goods:
Providing online, non-downloadable software in the healthcare field, namely, providing a software platform for members to access de-identified health data of individuals for collaboration and research purposes
Providing online, non-downloadable software for use in data aggregation, normalization, integration and analysis, data mining and predictive analytics of pharmaceutical, healthcare, and life sciences information
Providing online, non-downloadable software for analyzing data related to patient registries, clinical trials, clinical research and patient management in the pharmaceutical, healthcare, and life sciences fields
The provision of data as a service, namely, providing temporary use of online non-downloadable software for inputting, accessing, viewing, processing and analyzing health data of individuals and patient populations
Computer services, namely, designing, developing and managing application software related to pharmaceutical, healthcare and life sciences information
Data aggregation, normalization, integration and analysis, data mining and predictive analytics services for pharmaceutical, healthcare, and life sciences companies.